Anirvan Ghosh, Unity Biotechnology CEO

A month af­ter los­ing its lead pro­gram, Uni­ty Biotech­nol­o­gy cuts 30% of staff in re­struc­tur­ing

Uni­ty Biotech­nol­o­gy’s lead an­ti-ag­ing pro­gram faced the chop­ping block last month fol­low­ing a ma­jor Phase II flop. And now, 30% of its staff are next, as the com­pa­ny re­struc­tures to fo­cus on oph­thal­mol­o­gy and neu­rol­o­gy.

The staff re­duc­tion will leave San Fran­cis­co-based Uni­ty $UBX with 75 full-time em­ploy­ees by the end of the year. It’s yet an­oth­er blow to the celebri­ty-fund­ed biotech, which has been laser-fo­cused on clear­ing senes­cent cells to po­ten­tial­ly re­duce the symp­toms of ag­ing.

In the last 10 years, Uni­ty has at­tract­ed in­vestors like Jeff Be­zos, Pe­ter Thiel and Arch Ven­ture Part­ners’ Bob Nelsen — rak­ing in more than $200 mil­lion in fund­ing. But last month, it missed the mark in a 183-per­son Phase II study test­ing UBX0101 for os­teoarthri­tis of the knee. Pa­tients on the treat­ment arms showed vir­tu­al­ly no dif­fer­ence com­pared to pa­tients on the place­bo arm, and as a re­sult of the news, the biotech’s mar­ket val­ue plunged 60%.

De­spite the set­back, CEO Anir­van Ghosh re­mained con­fi­dent in Uni­ty’s pre­clin­i­cal pipeline. “Our con­fi­dence in senes­cent cells dri­ving dis­ease bi­ol­o­gy re­mains strong,” he told in­vestors last month. “Not on­ly be­cause of work we’ve done in­ter­nal­ly, but al­so be­cause of the wealth of da­ta from labs that con­tin­ue to in­di­cate both that senes­cent cells ac­cu­mu­late dur­ing dis­eases of ag­ing and that elim­i­nat­ing them with tar­get­ed mech­a­nisms can pro­vide ben­e­fit.”

The biotech is hop­ing to send its di­a­bet­ic mac­u­lar ede­ma can­di­date, UBX1325, in­to Phase I by the end of the year. It’s de­signed to tar­get Bcl-xL, thus elim­i­nat­ing senes­cent cells to po­ten­tial­ly treat age-re­lat­ed eye dis­eases. Plus, the biotech is keep­ing UBX1967 in its pock­et — a “mol­e­c­u­lar­ly dis­tinct back­up to UBX1325.”

If all goes ac­cord­ing to plan, Uni­ty ex­pects to dose the first pa­tients in a Phase I study of UBX1325 lat­er this year.

“Uni­ty is a pi­o­neer in the de­vel­op­ment of ther­a­peu­tics tar­get­ing senes­cent cells at the crux of many age-re­lat­ed dis­eases, and we will con­tin­ue to build on this sci­en­tif­ic foun­da­tion as we ad­vance our pipeline,” Ghosh said in a state­ment.

The com­pa­ny says the staff re­duc­tion will ex­tend its cash run­way through mid-2022, and it’s go­ing to keep push­ing its pipeline to­ward the clin­ic.

“Mov­ing for­ward we will have a lean­er and more ag­ile team, which is well-re­sourced to ad­vance our pipeline pro­grams to key mile­stones,” Ghosh added lat­er.

Illustration: Assistant Editor Kathy Wong for Endpoints News

How Pur­due's $272M ad­dic­tion pay­out fund­ed a new home for its dis­card­ed non-opi­oid re­search

Don Kyle spent more than 20 years working for Purdue Pharma, right through the US opioid epidemic that led to the company’s rise and eventual infamy. But contrary to Purdue’s focus on OxyContin, Kyle was researching non-opioid painkillers — that is, until the company shelved his research.

As the company’s legal troubles mounted, Kyle found an unlikely way to reboot the project. In 2019, he took his work to an Oklahoma State University center that’s slated to receive more than two-thirds of the state’s $272 million settlement with Purdue over claims that the drugmaker’s behavior ignited the epidemic of opioid use and abuse.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

President Joe Biden at the State of the Union address with Vice President Kamala Harris and House Speaker Kevin McCarthy (Patrick Semansky/AP Images)

The drug pric­ing pres­i­dent: Biden warns of ve­to for any IRA re­peal at­tempts

President Joe Biden made clear in his “finish the job” State of the Union address last night that one of those jobs to be finished is insulin prices.

Biden’s push again to tackle insulin prices, after Republicans rebuffed the idea last summer and just after Biden won Medicare drug price negotiations/caps via the Inflation Reduction Act, shows how heavily he’s leaning into this work.

Rupert Vessey, Bristol Myers Squibb head of research and early development

Up­dat­ed: R&D tur­bu­lence at Bris­tol My­ers now in­cludes the end of a $650M al­liance and the de­par­ture of a top re­search cham­pi­on

This morning biotech Dragonfly put out word that Bristol Myers Squibb has handed back all rights to its IL-12 clinical-stage drug after spending $650 million to advance it into the clinic.

The news arrives amid a turbulent R&D stage for the pharma giant, which late last week highlighted Rupert Vessey’s decision to depart this summer as head of early-stage R&D following a crucial three-year stretch after he jumped to Bristol Myers in the big Celgene buyout. During that time he struck a series of deals for Bristol Myers, and also shepherded a number of Celgene programs down the pipeline, playing a major role for a lineup of biotechs which depended on him to champion their drugs.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Utpal Koppikar, new Verily CFO

Ex­clu­sive: Ver­i­ly wel­comes Atara Bio­ther­a­peu­tics vet­er­an as new CFO

Verily, Alphabet’s life sciences outfit, has plucked a new CFO from the ranks of Atara Biotherapeutics, the company announced on Wednesday.

Utpal Koppikar joins Verily after a nearly five-year stint as CFO and senior VP at Atara, though his résumé also boasts roles at Gilead and Amgen.

The news follows a major reshuffling at Verily, including several senior departures earlier this year and a round of layoffs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.

Singer Nick Jonas is back at work for Dexcom, this time for its new G7 glucose monitor.

Dex­com's spokescelebri­ty Nick Jonas re­turns to Su­per Bowl in new glu­cose mon­i­tor com­mer­cial

Dexcom is going back to the Super Bowl with its pop singer and patient spokesperson Nick Jonas. Jonas takes center stage as the lone figure in the 30-second commercial showcasing Dexcom’s next-generation G7 continuous glucose monitoring (CGM) device.

Jonas’ sleight-of-hand tricks populate the commercial — he pinches his empty fingers together and pops them open to reveal the small CGM — even as he ends the ad, saying, “It’s not magic. It just feels that way.” Jonas then disappears in a puff of smoke.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.

Richard Francis, newly-appointed Teva CEO (Novartis via Facebook)

New Te­va CEO Richard Fran­cis repri­or­i­tizes to 'get back to growth'

Six weeks into his new role at the helm of Teva Pharmaceutical, Richard Francis said it’s time to “get back to growth,” starting with a good look at the company’s priorities.

The chief executive has kicked off a strategic review, he announced during Teva’s quarterly call, which will continue over the next several months and produce results sometime in the middle of 2023. That means some pipeline cuts may be in store, he told Endpoints News, while declining to offer much more detail.

Sanofi is renewing its #VaccinesForDreams campaign with more stories, such as Juan's in Argentina (Sanofi)

Sanofi re­news so­cial cam­paign to re­mind that vac­cines let peo­ple ‘Dream Big’

Sanofi is highlighting people’s dreams — both big and small — to make the point that vaccines make them possible.

The renewed “Dream Big” global social media campaign’s newest dreamer is Juan, a teacher in the Misiones rainforest in Argentina whose story is told through videos on Instagram and Sanofi’s website with the hashtag #VaccinesForDreams.

The campaign ties to Sanofi’s broader umbrella initiative “Vaccine Stories” to promote the value of vaccines and drive awareness of the need for improved vaccination coverage.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.

Bill Anderson, incoming Bayer CEO (David Paul Morris/Bloomberg via Getty Images)

Bay­er taps Roche's Bill An­der­son to lead phar­ma gi­ant as CEO

We now know where Roche’s ex-pharma chief Bill Anderson is going.

German pharma giant Bayer announced Wednesday that Anderson will be taking on the role as CEO, less than six weeks after Anderson stepped down from his perch at Roche as head of the group’s pharmaceutical division.

Roche announced back in December that Anderson would depart on Dec. 31 to “pursue opportunities outside of Roche.” His replacement, Genentech vet and Roche’s current head of global product strategy, Teresa Graham, will start her role in March.

Bill Haney, Dragonfly CEO (Dave Pedley/Getty Images for SXSW)

Drag­on­fly chief: Bris­tol My­ers shouldn’t blame IL-12’s clin­i­cal per­for­mance for de­ci­sion to scrap the deal — eco­nom­ics played a key role

Bristol Myers Squibb says the IL-12 drug they were developing out of Dragonfly Therapeutics was scrubbed from the pipeline for a simple reason: It didn’t measure up on clinical performance.

But Bill Haney, the CEO of Dragonfly, is taking issue with that.

The early-stage drug, still in Phase I development, has passed muster with Bristol Myers’ general clinical expectations, advancing successfully while still in Phase I, he says.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.